论文部分内容阅读
Imatinib Mesylate is widely used for the treatment of chronic myelogenous leukaemia (CML),and its effects on CML cells are influenced by several signalling proteins.The research is aimed at determining whether Wnt5a affects the effects of Imatinib Mesylate against BCR-ABL positive CML cells (K562 cells and KU812 cells) and which signalling proteins are involved in.